Navigation Links
Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action

CAMBRIDGE (UK). 8th July 2009 / b3c newswire / - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

We are extremely pleased with the outcome of this initial clinical study with FX125L said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L.

About Funxional Therapeutics Ltd.
Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.
For more information about FXT, please visit our web site ( or contact us by e-mail ( ).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.
BSCIs are one of the three proprietary technology platforms in FXTs portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.


Konstantinos Efthymiopoulos

CEO of Funxional Therapeutics

+44 1223 451095

b3c newswire

Related biology news :

1. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
2. Salk researchers successfully reprogram keratinocytes attached to a single hair
3. Model successfully predicts large river system fish diversity
4. Scientists successfully treat new mouse model of inflammatory bowel disease
5. Researchers successfully simulate photosynthesis and design a better leaf
6. MIT Holding, Georgia Southern University, and MEVLABS successfully test the PROVECTOR
7. A new milestone in the GMES Space Component Program successfully achieved
8. Life on Mars pregnancy test successfully launched
9. DOE Joint Genome Institute completes soybean genome
10. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
11. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
Post Your Comments:
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
Breaking Biology Technology: